Curly T C M Morris

发表

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

M. Beksac, H. Goldschmidt, N. Kröger, 2013, Blood.

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial

M. Beksac, H. Goldschmidt, N. Kröger, 2015, Bone Marrow Transplantation.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia

B. Pégourié, S. Iacobelli, G. Gahrton, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances.

P. Hari, S. Schönland, A. van Biezen, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Has Allogeneic Transplantation a Role in the Management of Plasma Cell Leukaemia? A Study on Behalf of the Myeloma Subcomittee of the Chronic Leukaemia Working Party of the EBMT

M. Kersten, S. Iacobelli, G. Gahrton, 2011 .

Primary plasma cell leukemia and autologous stem cell transplantation

S. Iacobelli, G. Gahrton, D. Niederwieser, 2010, Haematologica.

Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.

J. Snowden, J. Cavenagh, G. Cook, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Stem cell harvesting after bortezomib-based re-induction for myeloma relapsing after autologous transplant: results from the BSBMT/UKMF Myeloma X (Intensive) trial.

J. Snowden, J. Cavenagh, G. Cook, 2016 .

IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.

N. Kröger, S. Iacobelli, I. Yakoub-Agha, 2021, Clinical lymphoma, myeloma & leukemia.

Efficacy and outcome of autologous transplantation in rare myelomas

H. Goldschmidt, G. Morgan, S. Iacobelli, 2009, Haematologica.

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

G. Morgan, W. Gregory, J. Cavenagh, 2015, British journal of haematology.

The clinical outcome and toxicity of high‐dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British society of blood and marrow transplantation study

C. Fegan, J. Byrne, J. Snowden, 2006, British journal of haematology.

Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2018, Biology of Blood and Marrow Transplantation.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

W. Wiktor-Jedrzejczak, N. Kröger, S. Iacobelli, 2017, Haematologica.

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

D. Esseltine, J. Cavenagh, N. Curry, 2008, British journal of haematology.

Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT.

H. Goldschmidt, S. Iacobelli, G. Gahrton, 2009 .

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

N. Kröger, M. Boccadoro, G. Gahrton, 2016, Leukemia & lymphoma.

High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation

N. Kröger, S. Iacobelli, A. Nagler, 2017, Haematologica.

Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide

P. Chiusolo, R. Brand, G. Martinelli, 2014, Transfusion.

Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up.

H. Goldschmidt, S. Iacobelli, G. Gahrton, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

N. Kröger, A. Zander, R. Brand, 2010, British journal of haematology.

Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting

N. Kröger, G. Gahrton, G. Cook, 2017, Leukemia & lymphoma.

Bortezomib(Velcade®)-Thalidomide-Dexamethasone (VTD) Is Superior to Thalidomide-Dexamethasone (TD) In Patients with Multiple Myeloma (MM) Progressing or Relapsing After Autologous Transplantation

B. Pégourié, S. Iacobelli, G. Gahrton, 2010 .

PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

D. Esseltine, J. Stec, J. Cavenagh, 2005, British journal of haematology.

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

S. Montoto, S. Iacobelli, J. Sierra, 2022, Journal of clinical medicine.

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

N. Kröger, S. Iacobelli, N. Russell, 2019, Bone Marrow Transplantation.

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling

S. Iacobelli, P. Chevallier, D. Blaise, 2022, Haematologica.

Melphalan 140 mg/m2 or 200 mg/m2 for autologous trasnplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma

Christof, W. Wiktor-Jedrzejczak, N. Kröger, 2022 .

Re‐transplantation after bortezomib‐based therapy

J. Snowden, J. Cavenagh, G. Cook, 2011, British journal of haematology.

Evolution or revolution in multiple myeloma therapy and the role of the UK

G. Cook, Curly T C M Morris, 2020, British Journal of Haematology.

Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT

H. Goldschmidt, S. Iacobelli, G. Gahrton, 2008 .

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

D. Esseltine, J. Cavenagh, D. Schenkein, 2005 .

What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial

M. Drayson, J. Barratt, G. Cook, 2022, EJHaem.

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

J. Snowden, J. Cavenagh, G. Cook, 2015 .

Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia

P. Bartolomeo, G. Mufti, N. Kröger, 2016 .

Comparison of upfront tandem autologous–allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma

N. Kröger, S. Iacobelli, G. Gahrton, 2015, Bone Marrow Transplantation.

Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study.

S. Iacobelli, R. Brand, G. Gahrton, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

N. Kröger, M. Boccadoro, G. Gahrton, 2016, Leukemia & lymphoma.

The Role Of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In Patients With POEMS Syndrome: A Retrospective study Of The Plasma Cell Disorders Subcommittee Of The Chronic Malignancy Working Party Of The EBMT

S. Iacobelli, G. Leone, A. Nagler, 2013 .

The Roel of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT,

G. Leone, J. Byrne, G. Ossenkoppele, 2011 .